BSD Medical Bolsters U.S. MicroThermX® Support Team with Hiring of Shella Leahy

  BSD Medical Bolsters U.S. MicroThermX® Support Team with Hiring of Shella
  Leahy

Business Wire

SALT LAKE CITY -- July 23, 2014

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com)
today announced that it has hired Shella Leahy to provide technical, clinical,
educational and field support for its MicroThermX microwave ablation system in
the United States. Ms. Leahy will lead educational and training activities
with customers and sales representatives throughout the United States.

“We continue to make solid inroads in the education, adoption, and use of our
MicroThermX system in the United States,” said Brian Ferrand, BSD Vice
President of Domestic Sales of BSD Medical. “To that end, it is imperative we
make additional key hires to support our growing base of users. Shella is an
exceptional addition to our team with over fifteen years of medical device
experience. She practiced for many years as a Chief Technologist using
equipment with patients in a hospital environment and more recently worked at
a well-known, multi-billion market cap medical device company teaching medical
device usage at over eighty hospitals, giving her an excellent foundation from
both a customer and sales perspective. She will play an integral part in
supporting our recently announced distribution agreement efforts in the West
with Comed Medical Specialties.”

Ms. Leahy joins BSD from Hologic, Inc. a maker of premium diagnostic products,
medical imaging systems and surgical products serving the healthcare needs of
women, where she was responsible for interfacing with hospitals across
California to sell and train them on new diagnostic equipment. Prior to
Hologic, she spent more than a decade in hospital and clinical settings
involved in all aspects of medical imaging.

About the MicroThermX ^  Microwave Ablation System

The MicroThermX Microwave Ablation System is a compact, mobile,
state-of-the-art, proprietary system that includes a microwave generator,
single-patient-use disposable antennas, and a thermistor-based temperature
monitoring system. The innovative design of the MicroThermX is the first of
its kind that allows delivery of higher power levels using a single generator.
The MicroThermX utilizes innovative synchronous phased array technology that
was developed and patented by BSD to provide larger and more uniform zones of
ablation during a single procedure. The MicroThermX product line includes an
innovative, high-end disposable that is used in each ablation treatment, and
provides ongoing revenue streams for BSD. The soft tissue ablation world
market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug
Administration (FDA) has granted the Company a 510(k) clearance to market the
MicroThermX for ablation of soft tissue. BSD has also received CE Marking for
the MicroThermX System, which allows BSD to market the MicroThermX system in
Europe. CE marking is also recognized in many countries outside of the EU,
providing BSD the ability to market the MicroThermX to a number of
international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s MicroThermX
microwave ablation system has been developed as a stand-alone therapy to
employ precision-guided microwave energy to ablate (destroy) soft tissue. The
Company has developed extensive intellectual property, multiple products in
the market and established distribution in the United States, Europe and Asia.
Certain of the Company’s products have received regulatory approvals and
clearances in the United States, Europe and China. For further information
visit BSD Medical's website atwww.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

Financial Profiles
Tricia Ross, 310-622-8226
tross@finprofiles.com
 
Press spacebar to pause and continue. Press esc to stop.